Variants in *KITLG* predispose to testicular germ cell cancer independently from spermatogenic function

Alberto Ferlin, Manuel Pengo, Damiano Pizzol, Umberto Carraro, Anna Chiara Frigo¹ and Carlo Foresta

Section of Clinical Pathology and Centre for Human Reproduction Pathology, Department of Histology, Microbiology and Medical Biotechnologies, University of Padova, Via Gabelli 63, 35121 Padova, Italy

¹Department of Environmental Medicine and Public Health, University of Padova, 35100 Padova, Italy

(Correspondence should be addressed to A Ferlin; Email: alberto.ferlin@unipd.it)

Abstract

Epidemiological data suggest an association and a common pathogenetic link between male infertility and testicular germ cell tumor (TGCT) development. Genome-wide studies identified that TGCT susceptibility is associated with *KITLG* (c-KIT ligand), which regulates the formation of primordial germ cells, from which TGCT is believed to arise and spermatogenesis develops. In this study, we analyzed the link between *KITLG*, TGCT, and spermatogenic disruption by performing an association study between the *KITLG* markers rs995030 and rs4471514 and 426 TGCT cases and 614 controls with normal and abnormal sperm count. We found that TGCT risk was increased more than twofold per copy of the major G allele and A allele in *KITLG* rs995030 and rs4471514 (odds ratio (OR)=2.38, 95% confidence interval (95% CI)=1.81–3.12; OR=2.43, 95% CI=1.86–3.17 respectively), and homozygotes for the risk allele had a sevenfold increased risk of TGCT. *KITLG* markers were strongly associated with seminoma subtype (per allele risk increased more than threefold, homozygote risk increased by 13- to 16-fold) and weakly with nonseminoma. *KITLG* markers were not associated with sperm production, as no difference was observed in men with normozoospermia and azo–oligozoospermia, both in controls and in TGCT cases. In conclusion, this study provides evidence that *KITLG* variants are involved in TGCT development and they represent an independent and strong specific risk factor for TGCT independently from spermatogenic function. A shared genetic cause and a common pathogenetic link between TGCT development and impairment of spermatogenesis are not evident from this study.

Endocrine-Related Cancer (2012) 19 101–108

Introduction

Testicular cancer (TC) is the most common cancer in males aged 20–40 years, with a worldwide incidence of 7.5 per 100 000, but the rates vary considerably between countries and ethnic groups (Horwich *et al.* 2006). About 95% of all TCs are represented by testicular germ cell tumors (TGCTs), which include seminoma and nonseminoma histological types.

Although environmental factors clearly contribute to TGCT development, the genetic component is also strong and the proportion of TGCT susceptibility accounted for by the genetic effects is estimated at 25% (Czene *et al.* 2002). TGCT has high familial risks compared with most other cancer types that are generally no more than twofold (Dong & Hemminki

2001): brothers of individuals with TGCT have an 8- to 12-fold increased risk of disease, and sons of affected individuals have a four- to six-fold increased risk (Swerdlow *et al.* 1997, Hemminki & Li 2004). Despite this strong familial relative risk, early results from linkage studies identified a limited relationship with genetic factors (Crockford *et al.* 2006), suggesting that TGCT is a genetically complex trait.

The gr/gr deletion on the Y chromosome, which seems to increase TGCT risk twofold to threefold and is also associated with spermatogenic impairment (Ferlin *et al.* 2005, Stouffs *et al.* 2011), might account only for a limited number of cases because carrier frequency of this variant is low (2–3%; Nathanson *et al.* 2005). More recently, four genome-wide

association studies (GWAS) from UK and USA have reported association of TGCTs with six new loci (*KITLG*, *SPRY4*, *BAK1*, *DMRT1*, *TERT*, and *ATF7IP*; Kanetsky et al. 2009, 2011, Rapley et al. 2009, Turnbull et al. 2010). The strongest association for TGCT susceptibility was found for SNPs in *KITLG* (ligand for the membrane-bound receptor tyrosine kinase KIT) gene with a >2.5-fold increased risk of disease per major allele (Kanetsky et al. 2009, Rapley et al. 2009), which is the highest reported for any cancer to date (Chanock 2009). The *KITLG*–KIT system regulates the survival, proliferation, and migration of primordial germ cells (PGCs; Runyan et al. 2006, Boldajipour & Raz 2007), the cells from which spermatogonia and spermatocytes develop and from which TGCT is believed to arise. Accordingly, altered differentiation of PGCs is associated with the development of TGCT and infertility in mice (Heaney et al. 2008) and probably also in humans (Galan et al. 2006, Rajpert-De Meyts & Hoei-Hansen 2007).

The relationship between different aspects of PGC development, TGCT susceptibility, and spermatogenic disruption, and the well-known epidemiological data suggesting an association and a common pathogenetic link between male infertility and TGCT development (Skakkebaek et al. 2001, Horwich et al. 2006, Rajpert-De Meyts 2006), led us to perform the current association study to clarify the possible link between *KITLG*, TGCT, and spermatogenic disruption. In fact, analysis of *KITLG* variation in TGCT men with a history of infertility, even if suggested, was not tested in GWAS (Kanetsky et al. 2009, Rapley et al. 2009). We therefore analyzed the association between previously identified SNPs in *KITLG* (Kanetsky et al. 2009, Rapley et al. 2009) and TGCT cases and controls with normal and disrupted spermatogenesis.

Materials and methods

Cases and controls

TGCT cases ($n=426$) were recruited over the last 10 years among patients referred to our center for semen analysis. As a standard procedure, semen analysis is performed in every TGCT case just after TGCT diagnosis, before orchiectomy. To avoid confounding factors, selected TGCT cases had no history of cryptorchidism and familial history of TGCT and were affected by classic seminoma ($n=251$) or nonseminoma (including yolk sac, choriocarcinoma, and embryonal carcinoma; $n=175$), excluding mixed phenotypes. Extragonadal TGCTs were also excluded and all TGCT cases were unrelated.

Controls ($n=614$) were recruited among men referred to our center for standard semen analysis, and TC was excluded by andrological examination and testicular ultrasound. Standard semen analysis was performed in cases and controls according to World Health Organization protocol and subjects were considered as having a normal spermatogenesis when total sperm count was ≥ 40 million/ejaculate (World Health Organization 1999). Oligozoospermic subjects (sperm count <40 million/ejaculate) were further analyzed to exclude possible causes of spermatogenic impairment (seminal infection, sperm autoantibodies, varicocele, history of cryptorchidism and orchitis, Y chromosome microdeletions (Ferlin et al. 2007), karyotype anomalies, medication, fever in the previous month, systemic diseases, and endocrine disorders), so that oligozoospermia might be considered idiopathic. All cases and controls were from the northeast of Italy.

The study has been approved by the Local Institutional Review Board, and informed consent was obtained from each subject after full explanation of the purpose and nature of all the procedures used. The study has been conducted in accordance with the principles expressed in the Declaration of Helsinki.

KITLG variant analysis

KITLG polymorphisms were analyzed by direct sequencing (ABI PRISM 3730XL DNA Sequencer, Applied Biosystems, Monza, Italy). Genomic DNA was extracted from peripheral blood leukocytes using QIAamp DNA Blood Midi Kit according to the manufacturer's protocol (Qiagen). The oligonucleotide primers used for the analysis were the following: 5'-GCAAATTTGTTACTCATTCTGTGG-3' and 5'-CAGTACTGGCTCCCTTGTCAT-3' for rs995030; 5'-TGGGGAGGCAGAGGATAAAT-3' and 5'-TCATTGACATGCCTGAGACAC-3' for rs4474514.

Table 1 Characteristics of testicular germ cell tumor cases and controls

	Cases ($n=426$)		Controls ($n=614$)	
	No.	Percentage (%)	No.	Percentage (%)
Total				
Age (mean $\pm$ s.d.)		29.4 $\pm$ 6.2		35.2 $\pm$ 5.8
Tumor type				
Seminoma	251	58.9	–	–
Nonseminoma	175	41.1	–	–
Sperm count				
≥ 40 million/ejaculate	219	51.4	414	67.4
<40 million/ejaculate	207	48.6	200	32.6

Reagents and conditions for the PCR were 14.3 µl H₂O, 2.5 µl 10× Gold Buffer, 1.5 µl 25 mM MgCl₂ solution (from Applied Biosystems, Branchburg, NJ, USA), 2.5 µl dNTPs (2 mM; from Amersham Biosciences), 1 µl each primer (10 µM; from Sigma–Aldrich), 0.2 µl 5 U/µl AmpliTaq Gold (from Applied Biosystems), and 2 µl template (100 ng/µl). The PCR program on a thermal cycler (GeneAMP PCR System 2700, Applied Biosystems, Monza, Italy) was first-step denaturation at 94 °C for 10 min, followed by 37 cycles of 94 °C for 60 s, 58 °C for 60 s, 72 °C for 60 s, and a final extension step of 4 min at 72 °C.

Statistical analysis

Test for Hardy–Weinberg equilibrium (HWE) was performed with the use of the χ^2 goodness-of-fit test. The extent of linkage disequilibrium (LD) among SNPs was quantified using Lewontin’s *D'* value and the correlation coefficient *r*². Differences in allele and genotype distribution between cases and controls were tested with the use of Cochran–Armitage trend test. Odds ratios (ORs) and 95% confidence interval (95% CI) were estimated to assess the effect of each SNP on cancer risk using a logistic regression model. Allelic ORs and 95% CIs were estimated on the basis of a multiplicative model. *P* values were corrected to account for multiple comparisons using the false discovery rate Benjamini–Hochberg method. Two-sided raw and adjusted *P* values are reported, and adjusted *P* < 0.05 was considered to indicate statistical significance. Statistical analyses were conducted using SAS version 9.2 (SAS Institute, Inc., Cary, NC, USA).

Results

We studied 426 TGCT cases (251 classic seminoma and 175 nonseminoma) and 614 controls, and both groups were considered as having a normal spermatogenesis when total sperm count was ≥40 million/ejaculate (Table 1). Genotyping was performed for two SNPs in the *KITLG* gene, rs995030 and rs4471514. The two markers were in strong LD (*D'* > 0.95 and *r*² > 0.90) and in HWE both in controls and in cases.

We observed association of TGCT with both markers (corrected *P*_{trend} = 1.06 × 10^{−9} and 5.48 × 10^{−10} for rs995030 and rs4471514 respectively; Table 2). TGCT risk was increased more than twofold per copy of the major G allele and A allele in *KITLG* rs995030 and rs4471514 (OR = 2.38, 95% CI = 1.81–3.12; OR = 2.43, 95% CI = 1.86–3.17 respectively). Homozygotes for the risk allele had a sevenfold increased risk of TGCT (OR = 7.04, 95% CI = 2.10–

Table 2 Association of *KITLG* SNPs with testicular germ cell tumor (TGCT)

Marker ^b	Risk allele	Genotype count ^a		OR (95% CI)			Raw <i>P</i> trend ^e	Corrected <i>P</i>
		Controls (n = 614)	TGCT cases (n = 426)	Per allele	Heterozygote ^c	Homozygote ^d		
rs995030 G/A	G	398 (0.65)/192 (0.31)/24 (0.04)	350 (0.82)/73 (0.17)/3 (0.01)	2.38 (1.81–3.12)	3.04 (0.89–10.41)	7.04 (2.10–23.56)	2.39 × 10 ^{−10}	1.06 × 10 ^{−9}
rs4471514 A/G	A	388 (0.63)/197 (0.32)/29 (0.05)	347 (0.81)/75 (0.18)/4 (0.01)	2.43 (1.86–3.17)	2.76 (0.94–8.10)	6.48 (2.25–18.60)	4.88 × 10 ^{−11}	5.48 × 10 ^{−10}

^aNumber of individuals genotyped as homozygous for the risk allele/heterozygous for the risk allele/homozygous for the nonrisk allele.
^bdbSNP number and major/minor alleles.
^cOR for heterozygotes for the risk allele compared with homozygotes for the nonrisk allele.
^dOR for homozygotes for the risk allele compared with homozygotes for the nonrisk allele.
^eCochran–Armitage test for trend. Significant OR are in bold.

23.56; OR=6.48, 95% CI=2.25–18.60, for rs995030 and rs4471514 respectively) compared with homozygotes for the nonrisk minor allele. Interestingly, *KITLG* markers were strongly associated with seminoma and weakly with nonseminoma (Table 3): seminoma risk was increased more than threefold per copy of the major G allele and A allele in *KITLG* rs995030 and rs4471514 (OR=3.14, 95% CI=2.18–4.54; OR=3.20, 95% CI=2.24–4.58 respectively), and homozygotes for the risk allele had a extremely high increased risk of seminoma (OR=13.01, 95% CI=1.75–96.71; OR=16.00, 95% CI=2.16–118.24, for rs995030 and rs4471514 respectively) compared with homozygotes for the nonrisk minor allele. Nonseminoma risk was increased less than twofold per copy of the major G allele and A allele in *KITLG* rs995030 and rs4471514 (OR=1.73, 95% CI=1.22–2.46; OR=1.78, 95% CI=1.26–2.50 respectively), and only a trend for significant OR for homozygotes for the risk allele was observed.

KITLG markers were not associated with spermatogenic function. In fact, both in controls and in TGCT cases, allele and genotype distribution were not different between subjects with normal (≥ 40 million/ejaculate) and low sperm count (< 40 million/ejaculate; Table 4), and this behavior was maintained in seminoma/nonseminoma cases. More detailed analysis of genotype distribution with respect to the severity of spermatogenic impairment (azoospermia, severe oligozoospermia, moderate oligozoospermia, and normozoospermia) failed to find association between *KITLG* markers and sperm count, both in controls and in TGCT cases. Furthermore, the mean sperm number was not different among the different genotypes and alleles (data not shown). Confirming the lack of association between *KITLG* markers and spermatogenic function, the increased risk per copy of the major alleles in *KITLG* rs995030 and rs4471514 was similar in TGCT cases with low sperm count compared with controls with low sperm count (OR=2.18, 95% CI=1.53–3.11; OR=2.16, 95% CI=1.53–3.05, for rs995030 and rs4471514 respectively) and in TGCT cases with normal sperm count compared with controls with normal sperm count (OR=2.62, 95% CI=1.71–4.01; OR=2.75, 95% CI=1.80–4.20, for rs995030 and rs4471514 respectively; Table 5).

Discussion

Taken together, these data showed association of *KITLG* markers with TGCT, especially the seminoma subtype, independently from the spermatogenic function. By using one marker previously identified

Table 3 Association of *KITLG* SNPs with seminoma and nonseminoma testicular germ cell tumor

Marker	Risk allele	Seminoma OR (95% CI)			Nonseminoma OR (95% CI)			Raw P trend ^c	Corrected P
		Per allele	Heterozygote ^a	Homozygote ^b	Per allele	Heterozygote ^a	Homozygote ^b		
rs995030 G/A	G	3.14 (2.18–4.54)	4.25 (0.56–32.39)	13.01 (1.75–96.71)	1.73 (1.22–2.46)	2.43 (0.55–10.72)	4.04 (0.94–17.29)	0.0018	0.0026
rs4471514 A/G	A	3.20 (2.24–4.58)	5.30 (0.70–40.14)	16.00 (2.16–118.24)	1.78 (1.26–2.50)	1.91 (0.56–6.59)	3.31 (0.99–11.05)	0.0010	0.0016

^aOR for heterozygotes for the risk allele compared with homozygotes for the nonrisk allele.
^bOR for homozygotes for the risk allele compared with homozygotes for the nonrisk allele.
^cCochran–Armitage test for trend. Significant OR are in bold.

in US cases (rs4471514; Kanetsky *et al.* 2009) and one marker previously identified in UK cases (rs995030; Rapley *et al.* 2009), we therefore replicated in Italians a similar increased risk of disease per major allele (2.5-fold). We also confirmed the risk of TGCT only for homozygotes for the risk allele (sevenfold increase) and not for the heterozygotes. However, association was found only for seminoma and not for nonseminoma. Different hypotheses might explain this different result, including ethnic differences, histological classification, or different number of cases (although the numbers were similar: 175 nonseminoma in our series, 180 and 141 in the discovery and replication phase of the US study, and 241 and 171 in the discovery and replication phase of the UK study). Studies dealing with genetic predisposition of TGCT frequently found differences between seminoma and nonseminoma. The gr/gr deletion of the Y chromosome is strongly associated with seminoma than with nonseminoma (Nathanson *et al.* 2005), longer CAG repeats on the androgen receptor gene are mainly associated with nonseminoma (Giwerzman *et al.* 2004), and we also found higher association of FSH receptor (*FSHR*) polymorphisms only with nonseminoma (Ferlin *et al.* 2008), and on the contrary stronger association of hydroxysteroid (17-beta) dehydrogenase 4 (*HSD17B4*) markers with seminoma (Ferlin *et al.* 2010). Therefore, it might also be possible that the two classes of TGCTs might have different pathogenesis. Indeed, somatic KIT alterations are far more frequent in seminoma than in nonseminoma (Forbes *et al.* 2008).

Another possibility is related to the presence of possible confounding risk factors. In fact, both GWAS included subjects with familial history of TGCT and personal history of cryptorchidism (Kanetsky *et al.* 2009, Rapley *et al.* 2009), which represent to date the most important clinical risk factor for TGCT with a relative risk of 4.8 (Dieckmann & Pichlmeier 2004). On the contrary, they did not consider another important risk factor for TGCT, infertility, or low sperm count. Nevertheless, we did not observe association of *KITLG* markers with spermatogenic function, both in controls and in TGCT cases. Therefore, variations in *KITLG* seem to represent an independent and strong specific risk factor for TGCT.

KITLG–KIT pathway involvement in TGCTs is supported by numerous evidences: high expression of KIT, somatic activating mutations, and genomic amplification of *KIT* are frequently seen in TGCTs (especially seminomas; Izquierdo *et al.* 1995, Strohmeier *et al.* 1995, Bokemeyer *et al.* 1996, Rapley *et al.* 2004, McIntyre *et al.* 2005, Goddard *et al.* 2007); germline deletions of *Kitlg* increase susceptibility to

Table 4 Association of *KITLG* SNPs with sperm count in testicular germ cell tumor (TGCT) cases and controls

Marker	Controls ≥ 40 million total sperm (n = 414)	Controls < 40 million total sperm (n = 200)	TGCT ≥ 40 million total sperm (n = 219)	TGCT < 40 million total sperm (n = 207)
rs995030 G/A				
Allele (G/a)	666 (0.80)/162 (0.20)	322 (0.81)/78 (0.19)	394 (0.90)/44 (0.10)	379 (0.92)/35 (0.08)
Genotype (GG/Ga/aa)	267 (0.64)/132 (0.32)/15 (0.04)	131 (0.66)/60 (0.30)/9 (0.04)	177 (0.81)/40 (0.18)/2 (0.01)	173 (0.83)/33 (0.16)/1 (0.01)
P trend		0.9785		0.4191
rs4471514 A/G				
Allele (A/g)	654 (0.79)/174 (0.21)	319 (0.80)/81 (0.20)	390 (0.89)/48 (0.11)	379 (0.92)/35 (0.08)
Genotype (AA/Ag/gg)	258 (0.62)/138 (0.33)/18 (0.05)	130 (0.65)/59 (0.30)/11 (0.05)	174 (0.80)/42 (0.19)/3 (0.01)	173 (0.83)/33 (0.16)/1 (0.01)
P trend		0.7598		0.2176

		TGCT ≥ 40 million total sperm OR (95% CI)				TGCT < 40 million total sperm OR (95% CI)				
Marker	Risk allele	Per allele		Heterozygote ^a	Homozygote ^b	Raw P trend ^e		Corrected P		
srs95030 G/A	G	2.18 (1.53–3.11)	2.27 (0.50–10.35)	4.97 (1.12–21.98)	1.31 × 10 ⁻⁵	2.29 × 10 ⁻⁵	2.62 (1.71–4.01)	4.95 (0.60–40.80)	11.89 (1.49–94.99)	8.24 × 10 ⁻⁶
rs4471514 A/G	A	2.16 (1.53–3.05)	1.83 (0.51–6.50)	4.05 (1.74–13.94)	9.06 × 10 ⁻⁶	1.81 × 10 ⁻⁵	2.75 (1.80–4.20)	6.15 (0.76–49.79)	14.64 (1.87–114.81)	3.45 × 10 ⁻⁶

^aCochran–Armitage test for trend. Significant OR are in bold.

In conclusion, our study not only further supports that *KITLG* variants are involved in TGCT development but also highlights that they represent an

independent and strong specific risk factor for TGCT, independently from spermatogenic function. Therefore, a shared genetic cause and a common pathogenic link between TGCT development and impairment of spermatogenesis still remain to be elucidated.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported by the Italian Ministry of University and Research (MIUR; grant number 2007TKYYJR). The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author contribution statement

A Ferlin and C Foresta participated in study design. A Ferlin, D Pizzol, U Carraro, and C Foresta enrolled patients. A C Frigo undertook statistical analysis. M Pengo made molecular analyses. A Ferlin, M Pengo, and A C Frigo contributed to data collection and generation of tables and figures. A Ferlin had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors had full access to the original data, reviewed the data analyses, contributed to data interpretation and to the writing of the report, made final decisions on all parts of the report, and approved the final version of the submitted report.

References

- Blume-Jensen P, Jiang G, Hyman R, Lee KF, O’Gorman S & Hunter T 2000 Kit/stem cell factor receptor-induced activation of phosphatidylinositol 3'-kinase is essential for male fertility. *Nature Genetics* **24** 157–162. (doi:10.1038/72814)
- Bokemeyer C, Kuczyk MA, Dunn T, Serth J, Hartmann K, Jonasson J, Pietsch T, Jonas U & Schmoll HJ 1996 Expression of stem-cell factor and its receptor c-kit protein in normal testicular tissue and malignant germ-cell tumours. *Journal of Cancer Research and Clinical Oncology* **122** 301–306. (doi:10.1007/BF01261407)
- Boldajipour B & Raz E 2007 What is left behind – quality control in germ cell migration. *Science’s STKE : Signal Transduction Knowledge Environment* **383** pe16. (doi:10.1126/stke.3832007pe16)
- Chanock S 2009 High marks for GWAS. *Nature Genetics* **41** 765–766. (doi:10.1038/ng0709-765)
- Crockford GP, Linger R, Hockley S, Dudakia D, Johnson L, Huddart R, Tucker K, Friedlander M, Phillips KA, Hogg D *et al.* 2006 Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. *Human Molecular Genetics* **15** 443–451. (doi:10.1093/hmg/ddi459)
- Czene K, Lichtenstein P & Hemminki K 2002 Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish Family-Cancer Database. *International Journal of Cancer* **99** 260–266. (doi:10.1002/ijc.10332)
- Dieckmann KP & Pichlmeier U 2004 Clinical epidemiology of testicular germ cell tumors. *World Journal of Urology* **22** 2–14. (doi:10.1007/s00345-004-0398-8)
- Dong C & Hemminki K 2001 Modification of cancer risks in offspring by sibling and parental cancers from 2 112 616 nuclear families. *International Journal of Cancer* **92** 144–150. (doi:10.1002/1097-0215(200102)9999:9999 <::AID-IJC1147> 3.0.CO;2-C)
- Ferlin A, Tessari A, Ganz F, Marchina E, Barlati S, Garolla A, Engl B & Foresta C 2005 Association of partial AZFc region deletions with spermatogenic impairment and male infertility. *Journal of Medical Genetics* **42** 209–213. (doi:10.1136/jmg.2004.025833)
- Ferlin A, Arredi B, Speltra E, Cazzadore C, Selice R, Garolla A, Lenzi A & Foresta C 2007 Molecular and clinical characterization of Y chromosome microdeletions in infertile men: a 10-year experience in Italy. *Journal of Clinical Endocrinology and Metabolism* **92** 762–770. (doi:10.1210/jc.2006-1981)
- Ferlin A, Pengo M, Selice R, Salmaso L, Garolla A & Foresta C 2008 Analysis of single nucleotide polymorphisms of FSH receptor gene suggests association with testicular cancer susceptibility. *Endocrine-Related Cancer* **15** 429–437. (doi:10.1677/ERC-07-0257)
- Ferlin A, Ganz F, Pengo M, Selice R, Frigo AC & Foresta C 2010 Association of testicular germ cell tumor with polymorphisms in estrogen receptor and steroid metabolism genes. *Endocrine-Related Cancer* **17** 17–25. (doi:10.1677/ERC-09-0176)
- Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, Menzies A, Teague JW, Futreal PA & Stratton MR 2008 The catalogue of somatic mutations in cancer (COSMIC). *Current Protocols in Human Genetics*. (doi:10.1002/0471142905.hg1011S57)
- Galan JJ, De Felici M, Buch B, Rivero MC, Segura A, Royo JL, Cruz N, Real LM & Ruiz A 2006 Association of genetic markers within the *KIT* and *KITLG* genes with human male infertility. *Human Reproduction* **21** 3185–3192. (doi:10.1093/humrep/del313)
- Giwercman A, Lundin KB, Eberhard J, Ståhl O, Cwikiel M, Cavallin-Ståhl E & Giwercman YL 2004 Linkage between androgen receptor gene CAG trinucleotide repeat length and testicular germ cell cancer histological type and clinical stage. *European Journal of Cancer* **40** 2152–2158. (doi:10.1016/j.ejca.2004.06.004)
- Goddard NC, McIntyre A, Summersgill B, Gilbert D, Kitazawa S & Shipley J 2007 KIT and RAS signalling pathways in testicular germ cell tumours: new data and a review of the literature. *International Journal of Andrology* **30** 337–348. (doi:10.1111/j.1365-2605.2007.00769.x)

- Heaney JD, Lam MY, Michelson MV & Nadeau JH 2008 Loss of the transmembrane but not the soluble kit ligand isoform increases testicular germ cell tumor susceptibility in mice. *Cancer Research* **68** 5193–5197. (doi:10.1158/0008-5472.CAN-08-0779)
- Hemminki K & Li X 2004 Familial risk in testicular cancer as a clue to a heritable and environmental aetiology. *British Journal of Cancer* **90** 1765–1770. (doi:10.1038/sj.bjc.6601714)
- Horwich A, Shipley J & Huddart R 2006 Testicular germ-cell cancer. *Lancet* **367** 754–765. (doi:10.1016/S0140-6736(06)68305-0)
- Izquierdo MA, Van der Valk P, Van Ark-Otte J, Rubio G, Germa-Lluch JR, Ueda R, Scheper RJ, Takahashi T & Giaccone G 1995 Differential expression of the c-kit proto-oncogene in germ cell tumours. *Journal of Pathology* **177** 253–258. (doi:10.1002/path.1711770307)
- Jacobsen R, Bostofte E, Engholm G, Hansen J, Olsen JH, Skakkebaek NE & Moller H 2000 Risk of testicular cancer in men with abnormal semen characteristics: cohort study. *BMJ* **321** 789–792. (doi:10.1136/bmj.321.7264.789)
- Kanetsky PA, Mitra N, Vardhanabhuti S, Li M, Vaughn DJ, Letrero R, Ciosek SL, Doody DR, Smith LM, Weaver J et al. 2009 Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. *Nature Genetics* **41** 811–815. (doi:10.1038/ng.393)
- Kanetsky PA, Mitra N, Vardhanabhuti S, Vaughn DJ, Li M, Ciosek SL, Letrero R, D'Andrea K, Vaddi M, Doody DR et al. 2011 A second independent locus within DMRT1 is associated with testicular germ cell tumor susceptibility. *Human Molecular Genetics* **20** 3109–3117. (doi:10.1093/hmg/ddr207)
- Mahakali Zama A, Hudson FP III & Bedell MA 2005 Analysis of hypomorphic KitlSl mutants suggests different requirements for KITL in proliferation and migration of mouse primordial germ cells. *Biology of Reproduction* **73** 639–647. (doi:10.1095/biolreprod.105.042846)
- McIntyre A, Summersgill B, Grygalewicz B, Gillis AJ, Stoop J, van Gurp RJ, Dennis N, Fisher C, Huddart R, Cooper C et al. 2005 Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. *Cancer Research* **65** 8085–8089. (doi:10.1158/0008-5472.CAN-05-0471)
- Nathanson KL, Kanetsky PA, Hawes R, Vaughn DJ, Letrero R, Tucker K, Friedlander M, Phillips KA, Hogg D, Jewett MA et al. 2005 The Y deletion gr/gr and susceptibility to testicular germ cell tumor. *American Journal of Human Genetics* **77** 1034–1043. (doi:10.1086/498455)
- Rajpert-De Meyts E 2006 Developmental model for the pathogenesis of testicular carcinoma in situ: genetic and environmental aspects. *Human Reproduction Update* **12** 303–323. (doi:10.1093/humupd/dmk006)
- Rajpert-De Meyts E & Høi-Hansen CE 2007 From gonocytes to testicular cancer: the role of impaired gonadal development. *Annals of the New York Academy of Sciences* **1120** 168–180. (doi:10.1196/annals.1411.013)
- Rapley EA, Hockley S, Warren W, Johnson L, Huddart R, Crockford G, Forman D, Leahy MG, Oliver DT, Tucker K et al. 2004 Somatic mutations of KIT in familial testicular germ cell tumours. *British Journal of Cancer* **90** 2397–2401.
- Rapley EA, Turnbull C, Al Olama AA, Dermizakis ET, Linger R, Huddart RA, Renwick A, Hughes D, Hines S, Seal S et al. 2009 A genome-wide association study of testicular germ cell tumor. *Nature Genetics* **41** 807–810. (doi:10.1038/ng.394)
- Richiardi L & Akre O 2005 Fertility among brothers of patients with testicular cancer. *Cancer Epidemiology, Biomarkers & Prevention* **14** 2557–2562. (doi:10.1158/1055-9965.EPI-05-0409)
- Runyan C, Schaible K, Molyneaux K, Wang Z, Levin L & Wylie C 2006 Steel factor controls midline cell death of primordial germ cells and is essential for their normal proliferation and migration. *Development* **133** 4861–4869. (doi:10.1242/dev.02688)
- Skakkebaek NE, Rajpert-De Meyts E & Main KM 2001 Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. *Human Reproduction* **16** 972–978. (doi:10.1093/humrep/16.5.972)
- Stouffs K, Lissens W, Tournaye H & Haentjens P 2011 What about gr/gr deletions and male infertility? Systematic review and meta-analysis *Human Reproduction Update* **17** 197–209. (doi:10.1093/humupd/dmq046)
- Strohmeyer T, Reese D, Press M, Ackermann R, Hartmann M & Slamon D 1995 Expression of the c-kit proto-oncogene and its ligand stem cell factor (SCF) in normal and malignant human testicular tissue. *Journal of Urology* **153** 511–515. (doi:10.1097/00005392-199502000-00073)
- Swerdlow AJ, De Stavola BL, Swanwick MA & Maconochie NE 1997 Risks of breast and testicular cancers in young adult twins in England and Wales: evidence on prenatal and genetic aetiology. *Lancet* **350** 1723–1728. (doi:10.1016/S0140-6736(97)05526-8)
- Turnbull C, Rapley EA, Seal S, Pernet D, Renwick A, Hughes D, Ricketts M, Linger R, Nsengimana J, Deloukas P et al. 2010 Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer. *Nature Genetics* **42** 604–607. (doi:10.1038/ng.607)
- Walsh TJ, Croughan MS, Schembri M, Chan JM & Turek PJ 2009 Increased risk of testicular germ cell cancer among infertile men. *Archives of Internal Medicine* **169** 351–356. (doi:10.1001/archinternmed.2008.562)
- World Health Organization 1999 *WHO Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interaction*. Cambridge, UK: Cambridge University Press.

Received in final form 19 December 2011

Accepted 22 December 2011

Made available online as an Accepted Preprint
22 December 2011